EP Vantage Shifting CAR-Ts Into a Higher Gear

CkBxCsgWkAAEJdD
Chimeric antigen receptor T cell (CAR-T) therapy has indisputably become one of the industry’s hottest topics and the next 18 months could see the first CAR-T drugs filed for US approval. But behind the excitement for all things CAR-T lie a number of obstacles in their path to approval.

In its second deep-dive into the CAR-T space EP Vantage explores how much of an advantage it will be for the first company to achieve approval in a market that has never been tested and the ability to charge premium pricing can only be guessed at.

Download Report


Leave a Reply

Your email address will not be published. Required fields are marked *


Home / Regulatory Policy Left / EP Vantage Shifting CAR-Ts Into a Higher Gear